Silver, Richard T

Publications

Sort by

Co-Author Network

selected publications

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. American journal of hematology. 2020 Academic Article GET IT
Times cited: 89
Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3. Blood. 2020 Article GET IT
Times cited: 5
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Information Resource GET IT
Times cited: 842
Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. American journal of hematology. 2019 Article GET IT
Times cited: 1
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography. 2019 Academic Article GET IT
Times cited: 10
Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer medicine. 2019 Academic Article GET IT
Times cited: 14
Distinguishing essential thrombocythemia JAK2V617F from polycythemia vera: limitations of erythrocyte values. Haematologica. 2019 Academic Article GET IT
Times cited: 14
Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood cancer journal. 2018 Article GET IT
Times cited: 13
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leukemia research. 2018 Article GET IT
Times cited: 5
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018 Article GET IT
Times cited: 29
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. BMC cancer. 2018 Academic Article GET IT
Times cited: 16
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. American journal of hematology. 2017 Academic Article GET IT
Times cited: 24
Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. The Lancet. Haematology. 2017 Academic Article GET IT
Times cited: 233
A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017 Academic Article GET IT
Times cited: 122
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis. Cancer. 2017 Academic Article GET IT
Times cited: 28
Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera. Leukemia & lymphoma. 2017 Article GET IT
Times cited: 5
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. Journal of hematology & oncology. 2017 Academic Article GET IT
Times cited: 293
Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients. Haematologica. 2016 Article GET IT
Management of CML-blast crisis. Best practice & research. Clinical haematology. 2016 Information Resource GET IT
Times cited: 37
Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. Journal of the National Cancer Institute. 2016 Academic Article GET IT
Times cited: 81
Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. Hematology (Amsterdam, Netherlands). 2016 Academic Article GET IT
Times cited: 8
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. Clinical lymphoma, myeloma & leukemia. 2016 Academic Article GET IT
Times cited: 10
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia. 2016 Information Resource GET IT
Times cited: 78
Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood. 2016 Academic Article GET IT
Times cited: 38
Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2015 Academic Article GET IT
Times cited: 36
Management of chronic myeloid leukemia in blast crisis. Annals of hematology. 2015 Information Resource GET IT
Times cited: 41
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica. 2015 Academic Article GET IT
Times cited: 204
The hematocrit value in polycythemia vera: caveat utilitor. Leukemia & lymphoma. 2014 Article GET IT
Times cited: 7
Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two-photon imaging. Journal of thrombosis and haemostasis : JTH. 2014 Academic Article GET IT
Times cited: 22
Life, genes, and death in Ph- MPNs. Blood. 2014 Article GET IT
Times cited: 1
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia. 2014 Information Resource GET IT
Times cited: 30
JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. Haematologica. 2013 Article GET IT
Times cited: 31
Ruxolitinib for myelofibrosis--an update of its clinical effects. Clinical lymphoma, myeloma & leukemia. 2013 Information Resource GET IT
Times cited: 26
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013 Academic Article GET IT
Times cited: 137
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Haematologica. 2013 Academic Article GET IT
Times cited: 33
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013 Academic Article GET IT
Times cited: 73
Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. Haematologica. 2013 Academic Article GET IT
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013 Information Resource GET IT
Times cited: 1628
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis. British journal of haematology. 2013 Academic Article GET IT
Times cited: 85
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Academic Article GET IT
Times cited: 158
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 1615
In vivo two-photon excited fluorescence microscopy reveals cardiac- and respiration-dependent pulsatile blood flow in cortical blood vessels in mice. American journal of physiology. Heart and circulatory physiology. 2012 Academic Article GET IT
Times cited: 106
Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica. 2011 Academic Article GET IT
Times cited: 32
Treatment of polycythemia vera with imatinib mesylate. Leukemia research. 2011 Academic Article GET IT
Times cited: 12
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood. 2011 Academic Article GET IT
Times cited: 218
The treatment of essential thromobocytosis revisited. Blood. 2011 Article GET IT
Times cited: 3
Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Article GET IT
Times cited: 22
Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. Blood. 2011 Academic Article GET IT
Times cited: 108
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?. The oncologist. 2011 Academic Article GET IT
Times cited: 1
JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leukemia research. 2010 Academic Article GET IT
Times cited: 48
The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Blood. 2010 Academic Article GET IT
Times cited: 80
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Academic Article GET IT
The blast phase of chronic myeloid leukaemia. Best practice & research. Clinical haematology. 2009 Information Resource GET IT
Times cited: 22
Recombinant interferon alpha (rIFN alpha-2b) may retard progression of early primary myelofibrosis. Leukemia. 2009 Article GET IT
Times cited: 31
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica. 2009 Article GET IT
Times cited: 35
JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms. Nature genetics. 2009 Academic Article GET IT
Times cited: 324
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Academic Article GET IT
Times cited: 413
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Academic Article GET IT
Times cited: 309
Polycythemia vera and other polycythemia syndromes. Cancer treatment and research. 2008 Information Resource GET IT
Times cited: 1
Chronic myeloid leukemia--some topical issues. Leukemia. 2007 Editorial Article GET IT
Times cited: 8
A novel unconventional antigen MPD5 elicits anti-tumor humoral immune responses in a subset of patients with polycythemia vera. International journal of immunopathology and pharmacology. 2007 Academic Article GET IT
Times cited: 7
Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. The Journal of molecular diagnostics : JMD. 2007 Academic Article GET IT
Times cited: 64
Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis. American journal of clinical pathology. 2007 Academic Article GET IT
Times cited: 20
Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate. Current hematologic malignancy reports. 2007 Information Resource GET IT
Times cited: 1
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England journal of medicine. 2006 Academic Article GET IT
Times cited: 2730
Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer research. 2006 Academic Article GET IT
Times cited: 158
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2006 Academic Article GET IT
Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera. Clinical immunology (Orlando, Fla.). 2006 Academic Article GET IT
Times cited: 22
An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions. Journal of immunology (Baltimore, Md. : 1950). 2006 Academic Article GET IT
Times cited: 24
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?. Leukemia. 2006 Article GET IT
Times cited: 42
Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2. The New England journal of medicine. 2006 Article GET IT
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2006 Academic Article GET IT
Times cited: 10
The third International Congress on Myeloproliferative and Myelodysplastic Syndromes. Leukemia research. 2006 Conference Paper GET IT
Times cited: 2
Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2005 Academic Article GET IT
Times cited: 99
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005 Academic Article GET IT
Times cited: 707
Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. Current hematology reports. 2005 Information Resource GET IT
Times cited: 11
Current treatment of myelofibrosis. Clinical advances in hematology & oncology : H&O. 2005 Academic Article GET IT
Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia. Leukemia. 2005 Academic Article GET IT
Times cited: 15
Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonists. British journal of haematology. 2004 Academic Article GET IT
Times cited: 19
The second international congress on myeloproliferative and myelodysplastic syndromes. Leukemia research. 2004 Conference Paper GET IT
Times cited: 5
Myelofibrosis: thalidomide finds a new disease. Mayo Clinic proceedings. 2004 Editorial Article GET IT
Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study. International journal of oncology. 2004 Academic Article GET IT
Times cited: 19
Imatinib mesylate in polycythemia vera. Blood. 2004 Article GET IT
Times cited: 5
Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia. 2004 Academic Article GET IT
Times cited: 70
Chronic myeloid leukemia. Hematology/oncology clinics of North America. 2003 Information Resource GET IT
Times cited: 12
The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Experimental hematology. 2003 Academic Article GET IT
A hope for the future. Cancer investigation. 2003 Editorial Article GET IT
Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera. Leukemia. 2003 Article GET IT
Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cells. Molecular cancer research : MCR. 2003 Academic Article GET IT
Times cited: 12
Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013. Leukemia & lymphoma. 2003 Academic Article GET IT
Times cited: 9
Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leukemia & lymphoma. 2002 Academic Article GET IT
Times cited: 23
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002 Academic Article GET IT
Times cited: 475
Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. Cancer genetics and cytogenetics. 2002 Academic Article GET IT
Times cited: 22
Treatment of polycythemia vera with recombinant interferon. International journal of hematology. 2002 Academic Article GET IT
Times cited: 3
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002 Academic Article GET IT
Times cited: 941
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Academic Article GET IT
Times cited: 402
Marked ploidy and BCR-ABL gene amplification in vivo in a patient treated with STI571. Leukemia. 2001 Article GET IT
Times cited: 17
Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 2001 Academic Article GET IT
Times cited: 21
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2000 Academic Article GET IT
Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture. Cancer research. 2000 Academic Article GET IT
Times cited: 122
An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood. 1999 Information Resource GET IT
Times cited: 357
Atypical BCR and ABL D-FISH patterns in chronic myeloid leukemia and their possible role in therapy. Leukemia & lymphoma. 1999 Academic Article GET IT
Times cited: 45
Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer. Journal of cancer research and clinical oncology. 1999 Academic Article GET IT
Times cited: 5
A special fluorescent in situ hybridization technique to study peripheral blood and assess the effectiveness of interferon therapy in chronic myeloid leukemia. Blood. 1998 Academic Article GET IT
Times cited: 63
Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood. 1998 Academic Article GET IT
Times cited: 160
Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Annals of oncology : official journal of the European Society for Medical Oncology. 1998 Academic Article GET IT
Times cited: 78
Interferon alfa: effects of long-term treatment for polycythemia vera. Seminars in hematology. 1997 Academic Article GET IT
Times cited: 59
Value of molecular monitoring during the treatment of chronic myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997 Academic Article GET IT
Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: a Cancer and Leukemia Group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996 Academic Article GET IT
Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. The cancer journal from Scientific American. 1995 Academic Article GET IT
Times cited: 76
Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia. 1995 Academic Article GET IT
Times cited: 39
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study. Cancer chemotherapy and pharmacology. 1995 Academic Article GET IT
Times cited: 23
New Approaches to the Treatment of Cancer-Related Anemia. Symposium proceedings. New York, October 23, 1993. Seminars in oncology. 1994 Conference Paper GET IT
Times cited: 3
Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood. 1994 Academic Article GET IT
Times cited: 168
Combination trial of subcutaneous recombinant alpha 2 b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphoma. Medical and pediatric oncology. 1994 Academic Article GET IT
Times cited: 13
Unusual clonal evolution during blast crisis of chronic myeloid leukaemia (CML). European journal of cancer. 1994 Article GET IT
Times cited: 2
Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 93
Interferon-alpha 2b: a new treatment for polycythemia vera. Annals of internal medicine. 1993 Academic Article GET IT
Times cited: 65
Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. Journal of the National Cancer Institute. 1993 Academic Article GET IT
Times cited: 199
Identification of BCR/ABL-negative primitive hematopoietic progenitor cells within chronic myeloid leukemia marrow. Blood. 1993 Academic Article GET IT
Times cited: 57
Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. The Cancer and Leukemia Group B. Cancer. 1992 Academic Article GET IT
Times cited: 127
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytarabine and lomustine. A Cancer and Leukemia Group B study. Leukemia & lymphoma. 1992 Academic Article GET IT
Times cited: 2
Chronic myeloid leukemia. Current opinion in oncology. 1992 Information Resource GET IT
Times cited: 3
The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991 Academic Article GET IT
Times cited: 91
A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1991 Academic Article GET IT
Times cited: 78
Densitometric analysis of Southern blot autoradiographs and its application to monitoring patients with chronic myeloid leukemia. Leukemia. 1991 Academic Article GET IT
Times cited: 22
Recombinant interferon alpha in the treatment of polycythemia vera. Blood. 1991 Article GET IT
Times cited: 27
A new treatment for polycythemia vera: recombinant interferon alfa. Blood. 1990 Academic Article GET IT
Times cited: 57
Quality of life assessment of Hodgkin's disease survivors: a model for cooperative clinical trials. Oncology (Williston Park, N.Y.). 1990 Academic Article GET IT
Times cited: 50
Chronic myeloid leukemia. A perspective of the clinical and biologic issues of the chronic phase. Hematology/oncology clinics of North America. 1990 Information Resource GET IT
Times cited: 31
Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia. 1990 Academic Article GET IT
Times cited: 189
Recombinant gamma-interferon has activity in chronic myeloid leukemia. American journal of clinical oncology. 1990 Academic Article GET IT
Times cited: 8
A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443. Cancer investigation. 1990 Academic Article GET IT
Times cited: 9
A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989 Academic Article GET IT
Times cited: 27
Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia. American journal of human genetics. 1989 Academic Article GET IT
Times cited: 46
The karyotype of Philadelphia chromosome-negative, bcr rearrangement-positive chronic myeloid leukemia. Cancer genetics and cytogenetics. 1988 Academic Article GET IT
Times cited: 14
The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia. 1988 Academic Article GET IT
Times cited: 70
Recombinant interferon-alpha for treatment of polycythaemia vera. Lancet (London, England). 1988 Article GET IT
Times cited: 68
Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML). International journal of cancer. 1988 Academic Article GET IT
Times cited: 5
Clonal immunoglobulin gene rearrangements in chronic lymphocytic leukemia: a correlative study. American journal of hematology. 1988 Academic Article GET IT
Times cited: 16
The COP-BLAM programs: evolving chemotherapy concepts in large cell lymphoma. Seminars in hematology. 1988 Academic Article GET IT
Times cited: 43
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis-chloronitrosurea during the course of busulfan-maintained remission. Cancer investigation. 1988 Academic Article GET IT
Times cited: 4
Origin of near-haploidy in malignant hematopoietic cells. Leukemia research. 1988 Academic Article GET IT
Times cited: 11
Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematological oncology. 1988 Academic Article GET IT
Times cited: 60
Adoptive immunotherapy for stage IV renal cell carcinoma: a novel protocol utilizing periodate and interleukin-2-activated autologous leukocytes and continuous infusions of low-dose interleukin-2. The American journal of medicine. 1987 Academic Article GET IT
Times cited: 33
Utility of molecular genetic analysis of bcr rearrangement in the diagnosis of chronic myeloid leukemia. Cancer genetics and cytogenetics. 1987 Academic Article GET IT
Times cited: 27
A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B. Cancer. 1987 Academic Article GET IT
Times cited: 10
Intensive postremission therapy in adults with acute nonlymphocytic leukemia using various dose schedules of ara-C: a progress report from the CALGB. Cancer and Leukemia Group B. Seminars in oncology. 1987 Academic Article GET IT
Times cited: 51
Advances in chemotherapy for large cell lymphoma. Seminars in hematology. 1987 Academic Article GET IT
Times cited: 45
Length polymorphisms of the human Y chromosome in patients with chronic myelogenous leukemia. Cancer genetics and cytogenetics. 1987 Academic Article GET IT
Times cited: 2
Role of heterochromatin during preferential 9q;22q translocation in chronic myelogenous leukemia. Canadian journal of genetics and cytology. Journal canadien de genetique et de cytologie. 1986 Academic Article GET IT
Position of the Y-chromosome at somatic metaphase in patients with chronic myelogenous leukemia (CML). Experientia. 1986 Academic Article GET IT
Refractory anemias, pre-leukemia and myelodysplasias. Revista do Hospital das Clinicas. 1985 Academic Article GET IT
A randomized trial of CMF versus CMFVP as adjuvant chemotherapy in women with node-positive stage II breast cancer: a CALGB Study. World journal of surgery. 1985 Academic Article GET IT
Times cited: 18
Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study. Seminars in oncology. 1985 Academic Article GET IT
Times cited: 16
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 5
HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification. Cancer. 1985 Academic Article GET IT
Times cited: 5
Treatment of advanced endometrial carcinoma with doxorubicin and cisplatin: effects on both untreated and previously treated patients. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 29
Phase I-II trial of mitoxantrone in acute leukemia. Cancer treatment reports. 1985 Academic Article GET IT
Times cited: 53
Cytoreductive surgery. Obstetrics and gynecology. 1984 Article GET IT
Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood. 1984 Academic Article GET IT
Times cited: 94
A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. American journal of clinical oncology. 1984 Academic Article GET IT
Times cited: 70
Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients. Medical and pediatric oncology. 1984 Academic Article GET IT
Times cited: 6
Mitoxantrone in acute lymphoblastic leukemia. Cancer treatment reviews. 1983 Academic Article GET IT
Times cited: 3
Four-drug combination chemotherapy (methotrexate, cyclophosphamide, hexamethylmelamine, and CCNU) for non-small cell bronchogenic carcinoma: a Cancer and Leukemia Group B study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1983 Academic Article GET IT
Mitoxantrone in patients with acute leukemia in relapse. Cancer research. 1983 Academic Article GET IT
Times cited: 71
Administration of a complex chemotherapy regimen: inpatient versus outpatient treatment. Medical and pediatric oncology. 1983 Academic Article GET IT
Times cited: 2
Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and Leukemia Group B experience. Cancer. 1982 Academic Article GET IT
Times cited: 13
Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer. 1982 Academic Article GET IT
Times cited: 11
Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. Annals of internal medicine. 1982 Academic Article GET IT
Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982 Academic Article GET IT
Times cited: 404
Expression of Ia-antigens on normal and chronic myeloid leukemic human granulocyte-macrophage colony-forming cells (CFU-GM) is associated with the regulation of cell proliferation by prostaglandin E. Blood. 1982 Academic Article GET IT
Times cited: 27
Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981 Academic Article GET IT
Times cited: 371
A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Academic Article GET IT
Times cited: 39
The dying patient: a clinician's view. The American journal of medicine. 1980 Academic Article GET IT
Times cited: 4
Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. Cancer. 1980 Academic Article GET IT
Times cited: 58
Combination chemotherapy for terminal-phase chronic granulocytic leukemia: cancer and leukemia group B studies. Blood. 1980 Academic Article GET IT
Times cited: 69
Variant ph1 translocation in chronic myeloid leukemia. Blood. 1979 Article GET IT
Times cited: 6
A comparative trial of daunorubicin, cytosine arabinoside, and thioguanine, and a combination of the three agents for the treatment of acute myelocytic leukemia. Medical and pediatric oncology. 1979 Academic Article GET IT
Times cited: 31
Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leukemia research. 1979 Academic Article GET IT
Times cited: 33
Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up study. Medical and pediatric oncology. 1979 Academic Article GET IT
Times cited: 2
Splenectomy in chronic myeloid leukemia. Annals of internal medicine. 1978 Academic Article GET IT
Times cited: 24
Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma. Cancer. 1978 Academic Article GET IT
Times cited: 11
Morbidity of staging laparotomy in Hodgkin's disease. The American journal of medicine. 1978 Academic Article GET IT
Times cited: 23
Guidelines for protocol studies in chronic lymphocytic leukemia. American journal of hematology. 1978 Academic Article GET IT
Times cited: 34
Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood. 1977 Academic Article GET IT
Times cited: 143
High dose methotrexate with citrovorum factor in adult resistant lymphoma. Cancer. 1977 Academic Article GET IT
Times cited: 13
Piperazinedione in metastatic renal carcinoma. Cancer treatment reports. 1977 Academic Article GET IT
Times cited: 4
A new combination chemotherapy for resistant Hodgkin disease. JAMA. 1977 Academic Article GET IT
Times cited: 26
Value of biopsy in diagnosis of primary lymphosarcoma of marrow. Archives of internal medicine. 1977 Academic Article GET IT
Times cited: 2
Peritoneoscopy in Hodgkin disease. Confirmation of results by laparotomy. JAMA. 1976 Academic Article GET IT
Times cited: 35
Mediastinal irradiation for chronic lymphocytic leukemia. The American journal of medicine. 1976 Academic Article GET IT
Times cited: 11
Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia. Cancer. 1975 Academic Article GET IT
Times cited: 52
The bone marrow in polycythemia vera. Seminars in hematology. 1975 Academic Article GET IT
Times cited: 60
Letter: Acute hemolytic episodes 37 years apart. The New England journal of medicine. 1975 Academic Article GET IT
Diagnosis of plasma cell myeloma. American family physician. 1975 Academic Article GET IT
The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma. Medical and pediatric oncology. 1975 Academic Article GET IT
Association of Hodgkin disease and Gaucher disease. Archives of pathology. 1974 Academic Article GET IT
Times cited: 18
The chemotherapy of plasma cell myeloma and related disorders. Antibiotics and chemotherapy. 1974 Information Resource GET IT
Times cited: 10
The diagnosis of miliary tuberculosis: utility of peripheral blood abnormalities, bone marrow and liver needle biopsy. Journal of chronic diseases. 1973 Academic Article GET IT
Times cited: 33
The importance of bone marrow biopsy in the staging of patients with lymphosarcoma. Blood. 1973 Academic Article GET IT
Times cited: 16
The staging of Hodgkin's disease. Selective vs routine laparotomy. JAMA. 1973 Academic Article GET IT
Times cited: 11
Daunorubicin in the therapy of acute granulocytic leukemia. Cancer research. 1973 Academic Article GET IT
Times cited: 95
Evaluation of aniline mustard in patients with multiple myeloma. Cancer research. 1973 Academic Article GET IT
Times cited: 15
Intermittent therapy with 6-mercaptopurine (NSC-755) and methotrexate (NSC-740) given intravenously to adults with acute leukemia. Cancer chemotherapy reports. 1972 Academic Article GET IT
Times cited: 2
Treatment of adult leukemia with L-asparaginase (NSC-109229). Cancer chemotherapy reports. 1971 Academic Article GET IT
Times cited: 67
Importance of bone marrow biopsy in the clinical staging of Hodgkin's disease. Cancer. 1970 Academic Article GET IT
Times cited: 42
The treatment of chronic lymphocytic leukemia. Seminars in hematology. 1969 Information Resource GET IT
Times cited: 21
Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968 Academic Article GET IT
Times cited: 457
Characteristics of the terminal phase of chronic granulocytic leukemia. Blood. 1968 Academic Article GET IT
Times cited: 108
Hodgkin's disease: value of bone-marrow biopsy. The New England journal of medicine. 1968 Academic Article GET IT
Times cited: 1
Evaluation of tryptophan mustard (NSC-62403) in patients with plasmacytic myeloma. Cancer research. 1967 Academic Article GET IT
Times cited: 2
Influence of testosterone on the development of bone marrow at sites of transplanted bladder mucosa. Investigative urology. 1967 Academic Article GET IT
Platelet amino acid levels in essential thrombocytosis. Blood. 1966 Academic Article GET IT
Times cited: 2
USE OF TESTOSTERONE AND BUSULFAN IN THE TREATMENT OF MYELOFIBROSIS WITH MYELOID METAPLASIA. Blood. 1964 Academic Article GET IT
Times cited: 22
Studies of the plasma proteins in pregnancy using starch gel zone electrophoresis. Clinica chimica acta; international journal of clinical chemistry. 1962 Academic Article GET IT
Times cited: 2
Blood group studies of jungle Indians of the Mato Grosso. Transfusion. 1962 Academic Article GET IT
Times cited: 1
Blood studies of jungle Indians of the Upper Xingu River, Mato Grosso, Brazil. Bibliotheca haematologica. 1962 Academic Article GET IT
Evidence for a new allele in the Kidd blood group system in Indians of northern Mato Grosso, Brazil. Nature. 1960 Academic Article GET IT
Times cited: 13
Comparative study of 6-chloropurine and 6-mercaptopurine in acute leukemia in adults. Annals of internal medicine. 1959 Academic Article GET IT
Times cited: 4
A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958 Academic Article GET IT
Times cited: 94
Nitrogen, mineral, uric acid and basal metabolism studies in a case of adult acute leukemia with extensive osteolytic bone disease. The American journal of medicine. 1958 Academic Article GET IT
Times cited: 2
Fever, infection and host resistance in acute leukemia. The American journal of medicine. 1958 Academic Article GET IT
Times cited: 31
The role of the mature neutrophil in bacterial infections in acute leukemia. Blood. 1957 Academic Article GET IT
Times cited: 17
The neurologic manifestations of the acute leukemias: a clinical study. Annals of internal medicine. 1957 Academic Article GET IT
Times cited: 15

more ...

less ...

Background

education and training

M.D., Cornell University Medical College 1953
A.B., Cornell University 1950

Contact

full name

Richard T Silver

primary email

rtsilve@med.cornell.edu

VIVO Weill Cornell Medical College

Richard T Silver Professor Emeritus of Medicine

Publications

selected publications

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Background

education and training

Contact

full name

primary email